Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$27.73 +0.8%	$21.15	$16.10 ▼ $41.94	$3.50B	0.78	2.29 million shs	505,941 shs
MLTX MoonLake Immunotherapeutics	$53.81 -1.5%	$50.74	$31.42 ▼ $58.26	$3.46B	1.27	474,549 shs	368,093 shs
PTGX Protagonist Therapeutics	$56.93 +0.1%	$54.20	$33.31 ▼ $60.60	$3.54B	2.33	921,000 shs	266,922 shs
URGN Urogen Pharma	$19.17 +3.6%	$16.59	$3.42 ▼ $21.01	$886.34M	1.12	1.54 million shs	583,698 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	-1.61%	+0.62%	+40.48%	+62.94%	-31.39%
MLTX MoonLake Immunotherapeutics	-2.25%	+1.68%	-0.80%	+41.60%	+9.76%
PTGX Protagonist Therapeutics	-1.04%	+1.19%	+3.14%	+22.51%	+36.47%
URGN Urogen Pharma	-4.84%	-4.64%	-2.37%	+370.74%	+30.65%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLS Apellis Pharmaceuticals	4.2197 of 5 stars	3.3	1.0	4.4	4.1	2.5	0.6
MLTX MoonLake Immunotherapeutics	1.8458 of 5 stars	3.4	1.0	0.0	2.2	2.5	0.0
PTGX Protagonist Therapeutics	1.9282 of 5 stars	2.5	3.0	0.0	3.2	2.5	0.0
URGN Urogen Pharma	4.5236 of 5 stars	4.5	3.0	4.5	1.9	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.58	Moderate Buy	$34.12	23.04% Upside
MLTX MoonLake Immunotherapeutics	2.78	Moderate Buy	$74.43	38.33% Upside
PTGX Protagonist Therapeutics	3.00	Buy	$67.20	18.05% Upside
URGN Urogen Pharma	3.00	Buy	$32.00	66.96% Upside

Current Analyst Ratings Breakdown

Latest URGN, PTGX, MLTX, and APLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	URGN Urogen Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$36.00
8/11/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $40.00
8/7/2025	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	PTGX Protagonist Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$67.00 ➝ $69.00
8/6/2025	MLTX MoonLake Immunotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$74.00 ➝ $82.00
8/5/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
8/4/2025	APLS Apellis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$35.00 ➝ $37.00
8/1/2025	APLS Apellis Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$17.00 ➝ $19.00
8/1/2025	APLS Apellis Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$39.00 ➝ $40.00
8/1/2025	APLS Apellis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$52.00 ➝ $50.00
7/29/2025	APLS Apellis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$41.00 ➝ $46.00

(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$781.37M	4.48	N/A	N/A	$1.84 per share	15.07
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$7.09 per share	N/A
PTGX Protagonist Therapeutics	$434.43M	8.15	$4.47 per share	12.73	$11.33 per share	5.02
URGN Urogen Pharma	$90.40M	9.81	N/A	N/A	($0.21) per share	-91.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	-$197.88M	-$1.82	N/A	N/A	N/A	-30.24%	-116.09%	-26.72%	11/4/2025 (Estimated)
MLTX MoonLake Immunotherapeutics	-$118.94M	-$2.78	N/A	N/A	N/A	N/A	-40.98%	-35.81%	11/6/2025 (Estimated)
PTGX Protagonist Therapeutics	$275.19M	$0.70	81.36	N/A	N/A	24.88%	8.12%	7.41%	11/6/2025 (Estimated)
URGN Urogen Pharma	-$126.87M	-$3.32	N/A	N/A	N/A	-164.44%	-97,487.15%	-59.38%	11/5/2025 (Estimated)

Latest URGN, PTGX, MLTX, and APLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	URGN Urogen Pharma	-$0.82	-$1.05	-$0.23	-$1.05	$23.06 million	$24.22 million
8/6/2025	Q2 2025	PTGX Protagonist Therapeutics	-$0.53	-$0.55	-$0.02	-$0.55	$8.32 million	$5.55 million
8/5/2025	Q2 2025	MLTX MoonLake Immunotherapeutics	-$0.73	-$0.87	-$0.14	-$0.87	N/A	N/A
7/31/2025	Q2 2025	APLS Apellis Pharmaceuticals	-$0.44	-$0.33	+$0.11	-$0.33	$187.91 million	$171.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	2.90	3.77	3.16
MLTX MoonLake Immunotherapeutics	0.21	16.65	16.65
PTGX Protagonist Therapeutics	N/A	16.97	16.97
URGN Urogen Pharma	N/A	4.14	3.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
MLTX MoonLake Immunotherapeutics	93.85%
PTGX Protagonist Therapeutics	98.63%
URGN Urogen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.80%
MLTX MoonLake Immunotherapeutics	12.05%
PTGX Protagonist Therapeutics	4.90%
URGN Urogen Pharma	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	126.29 million	117.70 million	Optionable
MLTX MoonLake Immunotherapeutics	2	64.23 million	56.49 million	Optionable
PTGX Protagonist Therapeutics	120	62.21 million	59.16 million	Optionable
URGN Urogen Pharma	200	46.26 million	44.09 million	Optionable

URGN, PTGX, MLTX, and APLS Headlines

Recent News About These Companies

Partners Capital Investment Group LLP Invests $170,000 in Urogen Pharma $URGN

August 24 at 6:39 AM | marketbeat.com

UroGen Pharma to Present at Upcoming Investor Conferences

August 21, 2025 | globenewswire.com

Fox Run Management L.L.C. Takes Position in Urogen Pharma $URGN

August 21, 2025 | marketbeat.com

Piper Sandler Initiates Coverage of UroGen Pharma (URGN) with Overweight Recommendation

August 20, 2025 | msn.com

Piper starts ‘underestimated’ UroGen Pharma with an Overweight

August 19, 2025 | msn.com

UroGen Pharma initiated with an Overweight at Piper Sandler

August 18, 2025 | msn.com

UroGen Pharma: Targeting Profits In 2027

August 18, 2025 | seekingalpha.com

Oak Ridge Investments LLC Has $815,000 Position in Urogen Pharma (NASDAQ:URGN)

August 17, 2025 | marketbeat.com

Q3 EPS Estimates for Urogen Pharma Reduced by HC Wainwright

August 16, 2025 | marketbeat.com

HC Wainwright Has Weak Outlook for Urogen Pharma Q3 Earnings

August 16, 2025 | americanbankingnews.com

Urogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 10,000 Shares

August 15, 2025 | marketbeat.com

Urogen Pharma (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from Brokerages

August 14, 2025 | marketbeat.com

17,571 Shares in Urogen Pharma (NASDAQ:URGN) Acquired by Persistent Asset Partners Ltd

August 13, 2025 | marketbeat.com

UroGen Pharma’s Earnings Call: Achievements and Challenges

August 13, 2025 | msn.com

UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2025 Earnings Call Transcript

August 12, 2025 | msn.com

HC Wainwright Issues Pessimistic Forecast for Urogen Pharma (NASDAQ:URGN) Stock Price

August 12, 2025 | marketbeat.com

Urogen Pharma (NASDAQ:URGN) Releases Earnings Results, Misses Expectations By $0.20 EPS

August 11, 2025 | marketbeat.com

UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

August 10, 2025 | finance.yahoo.com

UroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call Transcript

August 9, 2025 | seekingalpha.com

UroGen Pharma Ltd. 2025 Q2 - Results - Earnings Call Presentation

August 9, 2025 | seekingalpha.com

Urogen Pharma (NASDAQ:URGN) Stock Price Down 14.4% Following Weak Earnings

August 8, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

URGN, PTGX, MLTX, and APLS Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

$27.73 +0.21 (+0.76%)

As of 03:15 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

MoonLake Immunotherapeutics NASDAQ:MLTX

$53.80 -0.83 (-1.51%)

As of 03:15 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Protagonist Therapeutics NASDAQ:PTGX

$56.92 +0.05 (+0.08%)

As of 03:15 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Urogen Pharma NASDAQ:URGN

$19.17 +0.67 (+3.60%)

As of 03:15 PM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time